Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
Indivior (NASDAQ/LSE: INDV) has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter brings 25 years of biopharmaceutical industry experience and will oversee Corporate Communications, Government Affairs, Policy and Advocacy.
Prior to joining Indivior, Procter served as Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led the successful launch of ZURZUVAE™. She previously held leadership positions at Alexion Pharmaceuticals and MedImmune, and worked as a health policy advisor in the U.S. House of Representatives.
Indivior (NASDAQ/LSE: INDV) ha nominato Vanessa Procter Vicepresidente Esecutiva delle Relazioni Aziendali, a partire dal 7 luglio 2025. Procter vanta 25 anni di esperienza nel settore biofarmaceutico e sarà responsabile delle Comunicazioni Aziendali, Affari Governativi, Politiche e Advocacy.
Prima di entrare in Indivior, Procter è stata Vicepresidente Senior delle Relazioni Aziendali presso Sage Therapeutics, dove ha guidato il lancio di successo di ZURZUVAE™. In precedenza ha ricoperto ruoli di leadership presso Alexion Pharmaceuticals e MedImmune, lavorando inoltre come consulente per le politiche sanitarie alla Camera dei Rappresentanti degli Stati Uniti.
Indivior (NASDAQ/LSE: INDV) ha designado a Vanessa Procter como Vicepresidenta Ejecutiva de Asuntos Corporativos, con efecto a partir del 7 de julio de 2025. Procter aporta 25 años de experiencia en la industria biofarmacéutica y supervisará las Comunicaciones Corporativas, Asuntos Gubernamentales, Políticas y Defensa.
Antes de unirse a Indivior, Procter fue Vicepresidenta Senior de Asuntos Corporativos en Sage Therapeutics, donde lideró el exitoso lanzamiento de ZURZUVAE™. Anteriormente ocupó cargos directivos en Alexion Pharmaceuticals y MedImmune, y trabajó como asesora de políticas de salud en la Cámara de Representantes de los Estados Unidos.
Indivior (NASDAQ/LSE: INDV)는 2025년 7월 7일부로 Vanessa Procter를 기업 업무 담당 수석 부사장으로 임명했습니다. Procter는 25년간의 바이오제약 산업 경력을 보유하고 있으며, 기업 커뮤니케이션, 정부 업무, 정책 및 옹호 활동을 총괄할 예정입니다.
Indivior에 합류하기 전, Procter는 Sage Therapeutics에서 기업 업무 수석 부사장으로 재직하며 ZURZUVAE™의 성공적인 출시를 이끌었습니다. 이전에는 Alexion Pharmaceuticals와 MedImmune에서 리더십 역할을 수행했으며, 미국 하원에서 보건 정책 고문으로 일한 경력이 있습니다.
Indivior (NASDAQ/LSE : INDV) a nommé Vanessa Procter au poste de Vice-Présidente Exécutive des Affaires Corporatives, à compter du 7 juillet 2025. Procter apporte 25 ans d'expérience dans l'industrie biopharmaceutique et supervisera les Communications Corporatives, les Affaires Gouvernementales, les Politiques et le Plaidoyer.
Avant de rejoindre Indivior, Procter était Vice-Présidente Senior des Affaires Corporatives chez Sage Therapeutics, où elle a dirigé le lancement réussi de ZURZUVAE™. Elle a auparavant occupé des postes de direction chez Alexion Pharmaceuticals et MedImmune, et a travaillé comme conseillère en politique de santé à la Chambre des représentants des États-Unis.
Indivior (NASDAQ/LSE: INDV) hat Vanessa Procter zum Executive Vice President für Unternehmensangelegenheiten ernannt, mit Wirkung zum 7. Juli 2025. Procter bringt 25 Jahre Erfahrung in der biopharmazeutischen Industrie mit und wird die Bereiche Unternehmenskommunikation, Regierungsangelegenheiten, Politik und Interessenvertretung leiten.
Vor ihrem Eintritt bei Indivior war Procter Senior Vice President für Unternehmensangelegenheiten bei Sage Therapeutics, wo sie den erfolgreichen Launch von ZURZUVAE™ leitete. Zuvor hatte sie Führungspositionen bei Alexion Pharmaceuticals und MedImmune inne und arbeitete als Gesundheitspolitikberaterin im US-Repräsentantenhaus.
- None.
- None.
"We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to priorities and executing successful multi-stakeholder strategies that drive patient access in complex regulatory environments. We look forward to her expertise and invaluable contributions as we pursue our mission to transform the lives of people living with opioid use disorder."
"I am honored to join Indivior at this transformative time for the Company," said Ms. Procter. "Public policy and community engagement are critical to address this significant public health challenge; providing the framework, funding and systems necessary to ensure treatment in the right place and at the right time. I look forward to working with the Indivior team and deepening our engagement with the people and communities we serve to further this important work."
Ms. Procter brings 25 years of experience in the biopharmaceutical industry, having led corporate and government affairs for multiple organizations. Most recently, Ms. Procter was Senior Vice President of Corporate Affairs at Sage Therapeutics, where she led a team that conditioned the environment for the successful product launch of ZURZUVAE™, the first pill for post-partum depression. In that role, she led corporate communications, investor relations, government affairs and patient advocacy. Prior to her time at Sage, she was Head of
Ms. Procter earned her B.A. in History from Gettysburg College.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-appoints-vanessa-procter-as-executive-vice-president-of-corporate-affairs-302499820.html
SOURCE Indivior PLC
FAQ
Who is the new Executive Vice President of Corporate Affairs at Indivior (INDV)?
What is Vanessa Procter's experience before joining Indivior (INDV)?
What will be Vanessa Procter's responsibilities at Indivior?
What is Indivior's main business focus?
